Protara Therapeutics, Inc. quarterly report, Q2 FY2015

Business context and reporting period

The filing is a Form 10-Q for the quarter ended June 30, 2015, filed by Proteon Therapeutics, Inc. The request metadata names Protara Therapeutics, Inc.; this is an apparent company-name mismatch that investors should verify. Proteon was a development-stage biopharmaceutical company focused on vonapanitase for vascular access failure in patients with chronic kidney disease. It had no product sales and was conducting Phase 3 trials.

Financial position and performance

Amounts below are in millions of dollars except per-share data.

At June 30, cash and cash equivalents were $16.82 million and available-for-sale investments were $57.92 million, totaling $74.74 million. Current assets were $75.79 million; current liabilities were $2.77 million. Total liabilities were $2.82 million, with no debt reported at quarter-end. Stockholders’ equity was $73.76 million and accumulated deficit was $119.53 million. Profitability and operating margins were not meaningful given the absence of product revenue and continuing development-stage losses.

For the six months, investing cash outflow was $43.61 million, primarily reflecting purchases of marketable securities, while financing provided $0.06 million. Cash and cash equivalents declined by $52.02 million; this included cash being shifted into available-for-sale investments and should not be read as operating burn alone. No dividend was expected in the foreseeable future.

Material changes versus prior comparable periods

• Second-quarter operating expenses rose $2.47 million year over year; six-month expenses rose $5.16 million. Management attributed the increases to Phase 3 trial activity, preparation for the second trial, manufacturing pre-validation, personnel, and public-company costs.
• Six-month net loss increased $4.26 million to $9.65 million. The comparison was partly offset by lower interest expense because convertible notes had been converted in May 2014, and by higher investment income.
• Operating cash use doubled to $8.47 million from $4.23 million for the six-month period, largely tracking the higher net loss.
• Available-for-sale investments increased to $57.92 million from $14.76 million at year-end 2014, while cash and cash equivalents fell from $68.84 million to $16.82 million.

Outlook, commentary, risks and unusual items

• Management estimated existing cash, cash equivalents and investments would fund operations into 2018, supporting first-trial results, enrollment in the second Phase 3 trial and CMC work. Elsewhere, the filing states existing funds were not expected to be sufficient to complete the second Phase 3 trial, indicating a likely future financing need.
• The first Phase 3 trial in radiocephalic AVFs was ongoing; the first patient in the second trial was enrolled in August 2015, after quarter-end. Management said a sufficiently compelling first-trial result could prompt discussions with the FDA about a possible BLA based on one trial, but FDA acceptance or approval was uncertain.
• The company emphasized that the Phase 2 primary efficacy endpoint did not show statistically significant benefit for the 30-microgram dose versus placebo. Favorable results in the radiocephalic AVF subgroup were from analyses not prespecified in the trial protocol and may not be replicated.
• Research costs, clinical enrollment and trial outcomes, regulatory requirements, manufacturing validation and access to additional capital could materially affect development timing, spending and runway. The company relied on third parties for manufacturing and clinical operations, including a sole or primary API supplier.
• Foreign-exchange contracts with $6.65 million notional value were entered into to reduce Swiss-franc exposure. They were not designated for hedge accounting; the company recorded $0.13 million in realized and unrealized losses in the first half and warned of potential earnings volatility.
• Management reported no material subsequent events and no legal proceedings expected to have a material adverse effect. Disclosure controls were judged effective at the reasonable-assurance level, with no material change in internal control over financial reporting reported.

Important facts for investors to verify

1. Confirm the issuer’s identity: the supplied filing is for Proteon Therapeutics, Inc., not Protara Therapeutics, Inc.
2. Assess the clinical evidence and the distinction between the nonsignificant Phase 2 primary endpoint and favorable, post hoc subgroup findings.
3. Track Phase 3 enrollment, results, the FDA’s position on any single-trial BLA, and the possibility of additional trials or delays.
4. Reconcile the stated runway into 2018 with management’s disclosure that current resources were not expected to fund completion of the second Phase 3 trial; evaluate financing and dilution risk.
5. Monitor manufacturing readiness, supplier concentration, Swiss-franc exposure and the effect of non-hedge-accounted currency contracts.